Contract manufacturing outsourcing (CMO) to India offers European brands 30–60% cost savings on finished-dose pharmaceutical and nutraceutical production versus European CMO rates — without sacrificing quality when the right manufacturer is selected. We identify manufacturers qualified for specific dosage forms, facilitate technical and quality discussions, and manage the commercial introduction on a success commission.
India–EU FTA Relevance
The India–EU FTA negotiations include provisions for mutual recognition of GMP inspections that, if ratified, would significantly reduce the regulatory friction in qualifying Indian CMOs for EU supply. This would lower the cost of qualification audits and accelerate the timeline from CMO selection to first commercial batch.
We charge 3–6% of the annual contract manufacturing value (first two years of the supply agreement), payable by the Indian CMO. A mandate engagement fee of €1,500–3,000 is charged for complex mandates and credited against the first-year commission.
All commissions confirmed in writing via NCNDA + Commission Agency Agreement before any introduction. Five-year non-circumvention protection. Payment typically net 10 business days from trigger event.
Subject-matter expertise + global network + documented deal process. The only intermediary model that works across borders.
01
CMO Manufacturer Identification
We identify Indian CMO facilities certified to WHO-GMP or EUGMP standards for specific dosage forms — screening for capacity, quality track record, EU export experience, and financial stability.
02
Technical Package Coordination
We facilitate the exchange of product technical dossiers, master manufacturing formulas, and stability data between the European brand owner and the Indian CMO — managing confidentiality protocols throughout.
03
Quality Agreement Facilitation
We coordinate the negotiation of Quality Agreements, supplier qualification questionnaires, and audit scheduling — working alongside the brand owner's QA team.
04
Commercial Term Negotiation
We facilitate commercial negotiations: MOQ, pricing per batch/unit, development fees, technology transfer charges, exclusivity, and supply security provisions.
05
Ongoing Supply Management Advisory
Post-agreement, we offer optional quarterly supply review facilitation to help both parties address batch rejection rates, lead time issues, or quality deviations constructively.
Full Bilateral Scope
Everything we can facilitate
A comprehensive scope of facilitation activity within this vertical — from first introduction through to repeat order management and multi-year supply agreements.
Veterinary pharma: oral and injectable dosage forms
Bilateral Flow
India ↔ World
🇮🇳 India Provides / Sources
🌍 Global Market Provides / Seeks
European pharma/nutra brand owners, MAHs, private label buyers
Indian WHO-GMP/EUGMP contract manufacturers (CMOs)
Indian CMOs seeking EU client diversification
European brands seeking cost-competitive, quality-assured manufacturing
Distribution Channel Development
We actively develop distribution channels via targeted prospecting with product samples, pilot shipments, and trial orders. Every new buyer relationship begins with a qualification call, followed by a documented sample or pilot order to prove commercial viability before any long-term commitment is made. This is the most effective route to sustainable bilateral volume.
Sector Intelligence
Historical Trends · Future Outlook · FTA Impact
Subject-matter intelligence underpinning our advisory and deal origination in this vertical. Updated annually by Vinod Kumar Jain (India-side) and Amit Jain (EU-side).
Historical Context
How This Sector Evolved
◆India's pharma CMO sector emerged from the generic manufacturing boom of the 1980s–90s — facilities built for domestic generic production were increasingly approached by international brands seeking cost-competitive contract manufacturing.
◆The pharmaceutical CMO concept evolved in India from simple toll manufacturing to full-service CMO — with facilities offering formulation development, stability studies, analytical services, and regulatory submission support alongside manufacturing.
◆EU pharma brands began exploring Indian CMOs in earnest from 2010 — driven by European CMO capacity constraints (particularly injectable and softgel), cost pressure from generic competition, and growing confidence in Indian GMP standards.
◆EUGMP inspection of Indian facilities — conducted by EU member state competent authorities (MHRA, ANSM, PEI) — grew steadily through the 2010s, with 80+ Indian facilities achieving EUGMP status by 2024.
◆The nutraceutical CMO market developed distinctly from pharmaceutical — Indian manufacturers offering FSSC 22000 and BRC-certified facilities for softgel, capsule, tablet, and powder formats to EU supplement brands seeking competitive production costs.
Future Outlook 2025–2030
Where This Sector Is Heading
▶GMP mutual recognition: the India–EU FTA negotiations include provisions for potential mutual recognition of GMP inspections — if ratified, this could reduce the cost and time of Indian facility qualification for EU supply by eliminating parallel inspection requirements.
▶Biologic CMO: Indian biosimilar manufacturers (Biocon Biologics, Dr. Reddy's, Hetero) building EU-GMP-compliant biologic production capacity — creating the next wave of Indian CMO capability targeting EU brand-owner outsourcing.
▶Continuous manufacturing: EU pharma innovators adopting continuous manufacturing for cost and quality consistency — a technology transfer opportunity for Indian CMOs willing to invest in next-generation production infrastructure.
▶Nutraceutical premiumisation: EU supplement brands moving from commodity vitamins to premium functional formats (liposomal, nanoemulsion, time-release) — Indian CMOs investing in advanced delivery technology to capture this higher-margin work.
▶CMO consolidation: Indian CMO market consolidating through M&A — larger groups (Alivus, Akums, Micro Labs CMO) offering EU brand owners scale, breadth, and financial durability that smaller facilities cannot match.
🚀
India–EU FTA Impact
High Impact
The most transformative FTA provision for CMO outsourcing would be GMP mutual recognition — reducing the average cost of Indian CMO qualification for EU supply from €150,000–500,000 (covering EUGMP inspection, quality system gap analysis, and repeated audit cycles) to a fraction of that amount. Even without formal mutual recognition, the FTA's regulatory cooperation chapter creates frameworks for information sharing between EU and Indian regulatory authorities that should accelerate inspection scheduling and reduce the current 12–24 month qualification timeline. For EU pharma brands, this converts Indian CMO outsourcing from a multi-year strategic project into an 8–12 month commercial decision.
Every trade mandate carries risk. The following are the most common risks in this vertical — and exactly how Global Nexus structures deals to address each one.
⚠ Risk
GMP Audit Failure During Qualification
EU brand qualifies Indian CMO — annual WHO-GMP inspection fails, supply disrupted, product recall risk.
✓ Mitigation
Pre-qualification audit mandated before any commercial supply begins. Global Nexus coordinates Bureau Veritas or SGS GMP gap assessment. Manufacturer must show minimum 2 consecutive clean WHO-GMP inspection cycles before mandate acceptance.
⚠ Risk
Batch Failure / Out of Specification
First commercial batch fails QC release — rejected by EU QP, wasting production run and delaying EU launch.
✓ Mitigation
Quality Agreement executed before any commercial production. EU QP appointed and briefed on product specifications. Pilot batch of 1,000-5,000 units produced and released by QP before full commercial run commences.
⚠ Risk
IP Leakage — Formula Replication
Indian CMO replicates EU brand formula for own product or for competitor — significant commercial damage.
✓ Mitigation
Technology Transfer Agreement with full IP ownership clause in favour of EU brand. Non-compete provision for 5 years post-contract. Formula kept as confidential know-how, not disclosed beyond minimum required production staff.
Practitioner Intelligence
Tips & Insights from the Field
Drawn from Vinod Kumar Jain's 30+ years of India-side manufacturing relationships and Amit Jain's EU-side buyer and regulatory experience. These are the insights that differentiate deals that close from those that don't.
EU nutraceutical and food supplement brands operate under lighter regulation than licensed pharmaceuticals — no EMA approval, no QP, faster launch. The WHO-GMP certified Indian manufacturer can supply EU nutraceutical brands immediately, building a relationship that can expand to licensed pharma as regulatory alignment progresses.
💡
Annual CMO contracts compound returns
Unlike one-off trade deals, CMO mandates generate commission annually on the ongoing contract value. A EUR 1M annual CMO contract at 4% commission generates EUR 40,000/year for the life of the relationship. Prioritise annual contracts over one-off supply mandates.
💡
Pilot batch investment prevents costly failures
EU brands who skip pilot batches to save time almost always incur greater cost from failed commercial batches. Budget EUR 15,000-50,000 for pilot batch production — it is the cheapest insurance against a EUR 200,000-500,000 commercial batch failure.
Ready to discuss a deal in this sector?
Porto, Portugal · +91 98881 47147 Panchkula, India · +91 98881 47147
Answers drawn from twenty-plus years of bilateral trade and advisory experience across this vertical.
Scheduling and conducting a GMP audit of an Indian facility typically takes 8–16 weeks from first contact. We pre-screen manufacturers to maximise the probability of a satisfactory audit outcome.
Indian CMOs generally charge a technology transfer fee (typically €5,000–30,000 depending on dosage form complexity) that covers development batches and validation costs. This is in addition to ongoing unit pricing.
Yes. We strongly recommend it. We can arrange factory visits and accompany buyers to facilitate introductions, technical discussions, and quality system walkthroughs.
Varies significantly by dosage form and facility. Nutraceutical capsules might have MOQs of 50,000 units; pharma tablets may require 100,000+. We clarify MOQs in the initial screening phase.
Yes. CMO relationship management, quality dispute resolution, and CMO switching programmes are services we offer for existing relationships that need a reset.
Have a question not answered here? Write to us directly — we respond to every enquiry personally within one working day.